GlassScriptPhysician profile
Peng Fan
NPI 1104801463
$231,581.24
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184K · 2020: $21K · 2021: $5,397 · 2022: $3,949 · 2023: $9,291 · 2024: $7,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $3,426 · Food and Beverage: $755 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,288.00 |
| Travel and Lodging | $3,425.88 |
| Food and Beverage | $755.43 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $113,901.41 | 2019-2024 | Prolia, Evenity, Enbrel |
| Novartis Pharmaceuticals Corporation | $36,027.08 | 2019-2022 | |
| Genzyme Corporation | $22,329.26 | 2019-2024 | |
| Pfizer INC. | $20,865.16 | 2019-2020 | |
| Abbvie INC. | $17,571.84 | 2019 | |
| Radius Health, INC. | $15,824.29 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $4,811.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $137.18 | 2019-2024 | |
| Glaxosmithkline, LLC. | $75.48 | 2020-2021 | |
| Janssen Biotech, INC. | $19.02 | 2019 | |
| Boston Scientific Corporation | $18.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peng Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.